. 2016 Nov 24;7(52):86914–86925. doi: 10.18632/oncotarget.13564

Table 1. Univariate analysis of various clinical endpoints.

Characteristic	N	5-year LRFS	χ²	P	5-year RRFS	χ²	P	5-year DMFS	χ²	P	5-year OS	χ²	P	5-year PFS	χ²	P
Sex			0.438	0.508		0.648	0.421		1.904	0.168		1.733	0.188		2.809	0.094
Male	394	91.2			95.9			81.9			78.9			73.9
Female	133	93.2			97.1			86.4			86.4			80.3
Age (years)			2.505	0.114		0.890	0.452		4.317	0.038		10.275	0.001		4.844	0.028
≤44	255	93.9			95.2			86.4			85.6			79.6
>44	272	89.1			97.5			79.3			75.7			71.3
T stage			14.250	0.003		0.984	0.805		11.975	0.007		22.287	0.000		20.965	0.000
T1	62	100.0			97.6			93.5			93.3			91.2
T2	156	93.1			96.2			85.8			86.8			77.5
T3	174	92.0			96.5			83.2			80.2			77.4
T4	135	85.8			96.0			74.7			65.8			64.5
N stage			5.375	0.146		2.686	0.443		16.088	0.001		14.285	0.003		22.575	0.000
N0	60	94.7			100.0			95.0			90.6			89.8
N1	184	94.4			96.0			86.1			81.4			80.7
N2	258	91.1			95.3			79.5			79.3			71.7
N3	25	71.4			95.7			67.2			67.8			44.8
Clinical stage			12.482	0.006		1.230	0.746		20.046	0.000		27.607	0.000		28.673	0.000
I	18	100.0			100.0			100.0			100.0			100.0
II	111	95.5			95.8			91.0			87.4			84.3
III	245	94.0			96.5			84.4			84.3			79.0
Iva-b	153	82.1			95.7			73.0			67.1			59.8
Concurrent chemotherapy			1.535	0.215		0.922	0.337		0.728	0.394		0.226	0.635		0.570	0.450
No	77	95.9			94.6			86.4			80.9			79.9
Yes	450	90.7			96.4			82.5			80.8			74.6

OS, overall survival;PFS, progression-free survival; LRFS, local recurrence-free survival;RRFS, regional recurrence-free survival, DMFS, distant metastasis-free survival